Mr. Rosencranz’s recent representations include advising:
- Mana Therapeutics in its $35 million Series A financing
- Kymera in its $102 million Series C financing
- Allego in its acquisition of Refract
- The underwriters in Royalty Pharma's $728 million follow-on public offering
- The initial purchasers on Arch Resources’ upsized to $155.25 million convertible senior notes
While in law school, Mr. Rosencranz served as a judicial intern at the U.S. District Court for the District of Massachusetts and at the Massachusetts Supreme Judicial Court. He also served as an editor of the Suffolk University Law Review.